Illumina develops and manufactures sequencing and array-based instruments and consumables for genetic and genomic analysis. The company's core offerings include sequencing platforms, reagents, flow cells, and library preparation kits, alongside specialized products such as whole-genome sequencing kits, targeted resequencing kits, and genotyping solutions. Additionally, Illumina provides noninvasive prenatal testing and product support services to its customer base.
The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, and commercial molecular diagnostic firms. Revenue is generated through direct sales to customers and distribution via life-science intermediaries across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Illumina operates with approximately 8,600 full-time employees and is headquartered in San Diego, California. The company was incorporated in Delaware in 1998.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $5.45 | $5.47 | +170.9% | |
| 2024 | $-7.69 | $-7.69 | -4.8% | |
| 2023 | $-7.34 | $-7.34 | +73.8% | |
| 2022 | $-28.00 | $-28.00 | -655.6% | |
| 2021 | $5.04 | $5.07 | +13.3% | |
| 2020 | $4.45 | $4.48 | +176.4% | |
| 2019 | $1.61 | $1.63 | +14.2% | |
| 2018 | $1.41 | $1.43 | +206.5% | |
| 2017 | $0.46 | $0.47 | -45.2% | |
| 2016 | $0.84 | $0.84 | +20.0% | |
| 2015 | $0.70 | $0.72 | -32.0% | |
| 2014 | $1.03 | $1.08 | +83.9% | |
| 2013 | $0.56 | $0.64 | +5.7% | |
| 2012 | $0.53 | $0.58 | +488.9% | |
| 2011 | $0.09 | $0.10 | -89.7% | |
| 2010 | $0.87 | $1.01 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-28 | 2026-02-12 | 0001110803-26-000024 | SEC ↗ |
| 2024-12-29 | 2025-02-12 | 0001110803-25-000019 | SEC ↗ |
| 2023-12-31 | 2024-02-16 | 0001110803-24-000010 | SEC ↗ |
| 2023-01-01 | 2023-02-17 | 0001110803-23-000023 | SEC ↗ |
| 2022-01-02 | 2022-02-18 | 0001110803-22-000013 | SEC ↗ |
| 2021-01-03 | 2021-02-17 | 0001110803-21-000015 | SEC ↗ |
| 2019-12-29 | 2020-02-11 | 0001110803-20-000018 | SEC ↗ |
| 2018-12-30 | 2019-02-12 | 0001110803-19-000013 | SEC ↗ |